Lupin introduces loteprednol etabonate ophthalmic suspension, 0.5% in US
Overview
Global pharma major Lupin Limited (Lupin) announced the launch of loteprednol etabonate ophthalmic suspension, 0.5%, in the United States.
Loteprednol etabonate bioequivalence
Loteprednol etabonate ophthalmic suspension, 0.5% is bioequivalent to Lotemax ophthalmic suspension, 0.5%, of Bausch & Lomb Inc.
Loteprednol etabonate: Indication
Loteprednol etabonate ophthalmic suspension, 0.5% is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.
It is also indicated for the treatment of post-operative inflammation following ocular surgery.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!